Ciclosporin kinetics in children after stem cell transplantation

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Ciclosporin is an immunosuppressant drug that is commonly used as prophylaxis against graft-versus-host disease (GVHD) after allogeneic haematopoietic stem cell transplantation (SCT) in children.• Therapeutic drug monitoring is necessary because of its unpredictable absorption and narrow therapeutic window.• Data on the pharmacokinetics of ciclosporin and the relation between its systemic exposure, as reflected by the AUC (area-under-the-curve), and the biological effect as GVHD prophylaxis are scarce in children after SCT. WHAT THIS STUDY ADDS• An adequate estimate of the systemic exposure of ciclosporin, following limiting sampling after intravenous and oral administration, can be obtained in children after SCT by determining the AUC using a two-compartment pharmacokinetic model with lag time in combination with a limited sampling strategy.• Large interindividual variability in ciclosporin clearance was found, which was independent of body weight; this finding justifies a dosing strategy distinct from that per kg body weight.• Limited sampling modelling may serve as a tool to study the relationship between systemic exposure (~AUC) and biological effects of ciclosporin, i.e. facilitation of engraftment, prevention of GVHD and avoidance of toxic effects of ciclosporin. AIMSTo develop a limited sampling strategy to determine ciclosporin systemic exposure [area-under-the-curve(AUC)]. This is meant to be the first step in a future study of the relationship between AUC and the biological effects of ciclosporin. METHODSThe pharmacokinetics of ciclosporin was investigated prospectively following stem cell transplantation (SCT) in 17 children, aged 1.8-16.1 years. Ciclosporin was given twice daily, intravenously over a short infusion of 2 h duration during the early post-SCT period, or orally later on, when oral medication was well tolerated. Parameter estimation was performed using nonlinear mixed effect modelling as implemented in the NONMEM program. Individual empirical Bayes estimates of clearance and distribution volume were correlated with the demographic variables. RESULTSPharmacokinetics was described adequately with a two-compartment model with lag time (population estimates: CL = 11.3 l h -1; Vc = 16.5 l; Vp = 59.9 l; t1/2 absorption = 0.78 h, tlag = 0.6 h). The AUCs, determined for the combination of trough level with one time point between 2 and 3 h after dosing, correlated very well with the reference AUC (r 2 = 0.97). No correlation was found between clearance and distribution volume, and the demographic patient variables length, body weight, age and glomerular filtration rate. CONCLUSIONA two-point limited sampling strategy, in combination with a Bayesian fitting procedure using the pharmacokinetic population model described, can adequately determine the AUC of ciclosporin. Since no correlation between clearance and body weight was found, dosing ciclosporin per kg bodyweight is not supported by the results of this study. We suggest starting with a fixed dose, fol...

Model-Based Determination of Effective Blood Concentrations of Cyclosporine for Neutrophil Response in the Treatment of Severe Aplastic Anemia in Children

“…This is consistent with previous PK studies of CsA in children (24,38). The estimated parameter values were comparable to those found in the literature (24,39).…”

“…Since no pharmacokinetic (PK) information in the absorption phase was available, parameters related to the absorption (bioavailability, lag time, and first-order absorption rate constant) were fixed, according to the literature (24).…”

CsA exposure is associated with acute GVHD and relapse in children after SCT

“…Therefore, in this study, CsA trough levels were obtained from 125 children transplanted for a haematological malignancy. These trough levels were used to estimate the AUC with a population PK model that has been described previously, 11 but was improved in this study. The model obtained allows prediction of the clearance and AUC of an individual patient at a certain moment, given the trough level, dosage, time after SCT, body weight and age.…”

“…Population PK analysis for AUC estimation A PK model, which was developed and described previously, 11 was updated with the data obtained for this study using Non-Linear Mixed Effects Modelling (NON-MEM, version VI release 1.2, Icon Development Solutions, Ellicott City, MD, USA). 12 Modelling results were analyzed using the statistical software package S-Plus for Windows (version 6.2 Professional, Insightful Corp., Seattle, USA).…”

Determination of initial i.v. CYA dosage to achieve target AUC values in pediatric hematopoietic stem cell transplant patients

“…19 Other investigators have also recommended that CYA be dosed according to BSA rather than ABW in children undergoing HSCT based on the lack of correlation between CYA clearance and ABW. 20 In addition, the practicality of using a single dose (65 mg/m 2 ) for all age groups rather than using two different doses (2.5 or 2.0 mg/kg) based on patient age has appeal. The results of this study are limited by the small sample size, particularly in some age groups.…”